Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 425

1.

Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.

Nihei K, Ogino T, Ishikura S, Kawashima M, Nishimura H, Arahira S, Onozawa M.

Jpn J Clin Oncol. 2005 Dec;35(12):745-52. Epub 2005 Nov 28.

PMID:
16314345
2.

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34.

PMID:
15752881
3.

Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.

Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, Shimizu S, Nonomura K, Koyanagi T, Miyasaka K.

Cancer J. 2003 Jul-Aug;9(4):268-76.

PMID:
12967137
4.

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA.

Cancer. 1999 Jun 1;85(11):2460-8.

PMID:
10357419
5.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):735-42.

PMID:
14967428
6.

Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.

Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A.

Radiother Oncol. 2005 Apr;75(1):74-82. Epub 2005 Apr 18.

PMID:
15878104
7.

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9. doi: 10.1016/j.ijrobp.2008.01.010. Epub 2008 Apr 11.

PMID:
18407435
8.

Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.

Liu M, Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M, Kwan W, McKenzie M, Morris J, Pai H, Tyldesley S, Wu J.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):59-67.

PMID:
14697421
9.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):706-13.

PMID:
15936549
10.

Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.

Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, Phillips TL, Roach M.

Urology. 2001 Jan;57(1):102-7.

PMID:
11164152
11.

Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.

Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):39-45. doi: 10.1016/j.ijrobp.2008.04.005. Epub 2008 Jun 4.

PMID:
18538488
12.

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

PMID:
18313526
13.

[Options of hypofractionation of proton boost in locally advanced prostate cancer].

Khmelevskiĭ EV, Pan'shin GA, Kancheli IN, Khoroshkov VS.

Vopr Onkol. 2012;58(6):787-94. Russian.

PMID:
23600305
14.

Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.

Karasawa K, Kaizu T, Niibe Y, Igaki H, Shinohara M, Tanaka Y, Matsuda T.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):208-12. Review.

PMID:
12694840
15.

Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.

Mock U, Bogner J, Georg D, Auberger T, Pötter R.

Strahlenther Onkol. 2005 Jul;181(7):448-55.

PMID:
15995838
16.

Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC.

Nikoghosyan AV, Schulz-Ertner D, Herfarth K, Didinger B, Münter MW, Jensen AD, Jäkel O, Hoess A, Haberer T, Debus J.

Acta Oncol. 2011 Aug;50(6):784-90. doi: 10.3109/0284186X.2011.584558.

PMID:
21767175
17.

Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.

Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):85-92. doi: 10.1016/j.ijrobp.2007.12.041. Epub 2008 Mar 20.

PMID:
18355982
18.

Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.

Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.

Brachytherapy. 2008 Jan-Mar;7(1):1-6. doi: 10.1016/j.brachy.2007.12.002.

PMID:
18299108
19.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, Kim J, Reagan R, Joyner R, Anscher MS.

Brachytherapy. 2009 Apr-Jun;8(2):191-6. doi: 10.1016/j.brachy.2009.01.002.

PMID:
19433320
20.

A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy.

Nichol A, Chung P, Lockwood G, Rosewall T, Divanbiegi L, Sweet J, Toi A, Bayley A, Bristow R, Crook J, Gospodarowicz M, McLean M, Milosevic M, Warde P, Catton C.

Radiother Oncol. 2005 Jul;76(1):11-7.

PMID:
15990187

Supplemental Content

Support Center